OBJECTIVE: Our objectives were to develop the population pharmacokinetic (PK) for pertuzumab and examine the variability of steady-state trough serum concentrations (C(SS,trough)) and exposure after fixed, body-weight-based, or body-surface area (BSA)-based dosing methods in cancer patients. METHODS: Pertuzumab was administered by i.v. infusion (every 3 weeks) either as a weight-based dose (0.5-15 mg/kg) or a fixed dose (420 or 1050 mg). Data from three clinical studies, comprising 153 patients and 1458 concentration-time points, were pooled for this analysis using NONMEM. RESULTS: A linear two-compartment model best described the data. Body weight and BSA were significant covariates affecting clearance (CL) and distribution volume (Vc), respectively. However, weight and BSA only explained small percentage of interpatient variability for CL and Vc, respectively. Simulation results indicated that PK profiles were very similar after the three dosing methods. Compared to fixed dosing, weight- and BSA-based dosing only reduced the population variability of C(SS,trough) moderately. CONCLUSION: A population PK model was developed for pertuzumab, the first monoclonal IgG1 antibody in a new class of agents known as HER dimerization inhibitors. In addition, our analyses demonstrate the feasibility of administering pertuzumab using a fixed dose in women with ovarian and breast cancers.
OBJECTIVE: Our objectives were to develop the population pharmacokinetic (PK) for pertuzumab and examine the variability of steady-state trough serum concentrations (C(SS,trough)) and exposure after fixed, body-weight-based, or body-surface area (BSA)-based dosing methods in cancerpatients. METHODS:Pertuzumab was administered by i.v. infusion (every 3 weeks) either as a weight-based dose (0.5-15 mg/kg) or a fixed dose (420 or 1050 mg). Data from three clinical studies, comprising 153 patients and 1458 concentration-time points, were pooled for this analysis using NONMEM. RESULTS: A linear two-compartment model best described the data. Body weight and BSA were significant covariates affecting clearance (CL) and distribution volume (Vc), respectively. However, weight and BSA only explained small percentage of interpatient variability for CL and Vc, respectively. Simulation results indicated that PK profiles were very similar after the three dosing methods. Compared to fixed dosing, weight- and BSA-based dosing only reduced the population variability of C(SS,trough) moderately. CONCLUSION: A population PK model was developed for pertuzumab, the first monoclonal IgG1 antibody in a new class of agents known as HER dimerization inhibitors. In addition, our analyses demonstrate the feasibility of administering pertuzumab using a fixed dose in women with ovarian and breast cancers.
Authors: Sharyn D Baker; Jaap Verweij; Eric K Rowinsky; Ross C Donehower; Jan H M Schellens; Louise B Grochow; Alex Sparreboom Journal: J Natl Cancer Inst Date: 2002-12-18 Impact factor: 13.506
Authors: Ron H J Mathijssen; Jaap Verweij; Maja J A de Jonge; Kees Nooter; Gerrit Stoter; Alex Sparreboom Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: Hyun-Soo Cho; Karen Mason; Kasra X Ramyar; Ann Marie Stanley; Sandra B Gabelli; Dan W Denney; Daniel J Leahy Journal: Nature Date: 2003-02-13 Impact factor: 49.962
Authors: Floris A de Jong; Ron H J Mathijssen; Rujia Xie; Jaap Verweij; Alex Sparreboom Journal: Clin Cancer Res Date: 2004-06-15 Impact factor: 12.531
Authors: Shuang Bai; Karin Jorga; Yan Xin; Denise Jin; Yanan Zheng; Lisa A Damico-Beyer; Manish Gupta; Meina Tang; David E Allison; Dan Lu; Yi Zhang; Amita Joshi; Mark J Dresser Journal: Clin Pharmacokinet Date: 2012-02-01 Impact factor: 6.447
Authors: Chee M Ng; Erin Dombrowsky; Hopi Lin; Michelle E Erlich; David E Moody; Jeffrey S Barrett; Walter K Kraft Journal: Pharmacotherapy Date: 2015-07-14 Impact factor: 4.705
Authors: Yan Xin; Shuang Bai; Lisa A Damico-Beyer; Denise Jin; Wei-Ching Liang; Yan Wu; Frank-Peter Theil; Amita Joshi; Yanmei Lu; John Lowe; Mauricio Maia; Rainer K Brachmann; Hong Xiang Journal: Pharm Res Date: 2012-06-16 Impact factor: 4.200